Martino Introna

Ospedale Papa Giovanni XXIII — Italy

Immunology and Microbiology · Life Sciences

72h-index17.7kcitations294works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(70), CAR-T cell therapy research(51), Mesenchymal stem cell research(49), Hematopoietic Stem Cell Transplantation(40), Chronic Lymphocytic Leukemia Research(36)

Publications293 total

Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches
Cancer Immunology Immunotherapy·2025· 1 citedOpen Access
Allogenic donor-derived cytokine-induced killer (CIK) cells as a safe post-transplant treatment for disease recurrence in the setting of HLA-mismatched donors
Blood·2025
Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody
Cancer Immunology Immunotherapy·2025· 1 citedOpen Access
Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability
Journal of Translational Medicine·2025· 2 citedOpen Access
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation
Blood Cancer Journal·2025· 9 citedOpen Access
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation
Universität Zürich, ZORA·2025Open Access
Cord Blood-Derived Carcik Cells As Off-the-Shelf Non-Viral Cell Therapy for Hematological Malignancies
Blood·2024Open Access
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells
Frontiers in Immunology·2024· 4 citedOpen Access
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab
Antibodies·2024· 4 citedOpen Access
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
Blood Cancer Journal·2024Open Access
Optimization and validation of in vivo flow cytometry <scp>chimeric antigen receptor T</scp> cell detection method using <scp>CD19his</scp> indirect staining
Cytometry Part A·2023· 4 citedOpen Access
A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome
JCI Insight·2023· 10 citedOpen Access
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)
Journal of the American Society of Nephrology·2023· 80 citedOpen Access
Potency assays and biomarkers for cell-based advanced therapy medicinal products
Frontiers in Immunology·2023· 26 citedOpen Access
Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
Blood·2022· 6 cited
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
Blood·2022· 2 cited
Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab
Blood·2022
Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical Trial
Journal of the American Society of Nephrology·2022
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
Cancers·2022· 46 citedOpen Access
A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies
Cytotherapy·2022· 15 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Josée Golay(28), Alessandro Rambaldi(22), Alberto Mantovani(13), Gianmaria Borleri(10), Chiara Capelli(9), Giuseppe Remuzzi(7), Andrea Biondi(7), Marina Morigi(6), Cinzia Rota(6), Giuseppe Peri(5), Giuseppe Gaipa(5), Sergio Bernasconi(4), Francesco Tedesco(4), Tiziano Barbui(4), Ariela Benigni(4), Norberto Perico(4), Elisa Gotti(4), Paola Cassis(4), Marina Noris(4), Massimiliano Manganini(4)